Sustainability & Climate

Fulgent Genetics reports revenue growth but faces a pivotal year with a major customer loss, betting its future on strategic acquisitions and a promising drug pipeline.

MedX Health Corp. lands a crucial $2.7M in initial funding, aiming for $5M to expand its skin-screening tech into occupational health and manage debt.

Startup World Cup's 'East Meets West' event positions Hawaii as a crucial hub for cross-Pacific innovation, with a $1M prize and Tim Draper in attendance.

Natural Resource Partners reports robust cash flow and near-zero debt, but severe headwinds in coal and soda ash markets test its long-term strategy.

Positive metallurgy results for West Graham pave a path to production, while a massive new anomaly at the LKE Project hints at a major discovery.

Lanvin Group promotes an insider to CEO of its struggling Wolford brand, betting on his turnaround expertise to navigate financial headwinds and a changing market.

After a 25-year era of global growth, Lansinoh appoints Julie Talbot to redefine parental support and scale a new, empathetic vision worldwide.

As part of a city-wide push, Lingnan University showcases its tech-infused liberal arts model to global leaders, aiming to boost the 'Study in Hong Kong' brand.

A new plan offers to wipe out electricity usage bills for Aussie solar homes, but does the 'zero bill' dream come with a catch? We investigate.

Decades of disinvestment have left rural Maryland behind. Now, a new initiative aims to unlock billions by empowering local leaders with powerful financial tools.

The new Brightspeed Bright Future Tech Lab at Orange High School is more than a prize; it's a new model for education and corporate investment.

Orion Group Holdings' strategic acquisition of J.E. McAmis, advised by ACT Capital, targets a booming infrastructure market with specialized expertise.

Morgan Stanley Direct Lending Fund reports lower Q4 NII and cuts its dividend, while launching a new joint venture to spur long-term strategic growth.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

Structure Therapeutics reports strong Phase 2 data for its oral obesity pill, aleniglipron, positioning it as a key contender in the race for pill-based GLP-1s.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With clinical results converging, a new report reveals the real GLP-1 battle is fought in patent filings, not labs, deciding who wins this $100B+ market.

Intelligent power management firm Eaton raises its dividend 6%, backed by record 2025 earnings and a strategic focus on electrification and digitalization.

New research suggests BMI is obsolete. If waistlines are included, up to 70% of Americans could be obese, challenging the entire wellness industry.